Mode
Text Size
Log in / Sign up
N/A Completed N=110 Diagnostic

Evaluation of the A1CNow+ Test Kit

Source: ClinicalTrials.gov NCT00798486 ↗
Enrolled (actual)
110
Serious AEs
0.0%
Results posted
Mar 2010
Primary outcomePrimary: Number of A1C Results Either Equal To Or Within +/- 13.5% of the Laboratory Method (ACCURACY) — 94; 71 number of A1c results

Summary

The purpose of this study was to assure that consumers can successfully use the new version of A1CNow+ along with revised instructional materials.

Outcome Measures

OutcomeResultp-value
PRIMARY
Number of A1C Results Either Equal To Or Within +/- 13.5% of the Laboratory Method (ACCURACY)
94; 71 —
SECONDARY
Average Within Subject Coefficient of Variation CV (PRECISION)
4.57 —
SECONDARY
Percentage of Subjects Who Experienced First Time Failures (FTF) During Testing
11; 40 —
SECONDARY
Number of Participants Who Provided These Ratings For Overall Testing Experience With A1C Test Kit
65; 38; 7; 0 —

Eligibility Criteria

Inclusion Criteria

  • Adults (age 18 and older) approximately 80% being ≤55 years old
  • Persons with:
  • known diabetes (type 1 or type 2) and pre-diabetes - approximately 85% of subject population per site
  • no known diagnosis of diabetes - approximately 15% of subject population per site
  • Individuals who are interested in performing a test using the kit at home
  • Individuals willing to complete all study procedures (including venous draw and allowing site staff to perform finger punctures)
  • Individuals who are able to speak, read, and understand English
  • Individuals able to read out loud the first 5 lines of the A1C Test Kit instructional materials to demonstrate ability to read the print (may use glasses, if needed)

Exclusion Criteria

  • Individuals taking prescription anticoagulants (such as Warfarin or heparin) or have clotting problems that may prolong bleeding. (Taking Plavix or aspirin daily is not excluded)
  • Individuals with known Rheumatoid Arthritis or other condition causing significant impairment of manual dexterity
  • Individuals with a known hemoglobin variant such as HbS or HbC
  • Individuals with any known disorder of the blood or blood-forming organs (such as recovery from blood loss, hemolytic anemia, or iron deficiency anemia)
  • Individuals who have received a blood transfusion within the 4 months prior to the study.
  • Persons with known infection with a bloodborne pathogen (e.g. HIV, hepatitis)
  • Individuals working for a competitive medical device company
  • Individuals who have participated in previous studies on the A1CNow+ product
  • Persons missing a digit or partial digits on the hand
  • Individuals with the following impairments which, in the opinion of the investigator, would seriously compromise the integrity of the study:
  • Significant visual impairment
  • Significant hearing impairment
  • Cognitive disorder
  • Any other condition as per investigator's discretion
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00798486). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search